巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

已收盘 07-22 16:08:03

29.600

+0.660

+2.28%

最高29.660	最低28.380	成交量549.67万
今开29.000	昨收28.940	日振幅4.42%
总市值314.35亿	流通市值314.35亿	总股本10.62亿
成交额1.60亿	换手率0.52%	流通股本10.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":29.6,"timestamp":1784707683005,"preClose":28.94,"halted":0,"volume":5496704,"delay":0,"changeRate":0.02280580511402903,"floatShares":1061999999,"shares":1061999999,"eps":1.809999,"marketStatus":"已收盘","change":0.66,"latestTime":"07-22 16:08:03","open":29,"high":29.66,"low":28.38,"amount":159669975,"amplitude":0.044229,"askPrice":29.6,"askSize":61200,"bidPrice":29.54,"bidSize":20200,"shortable":3,"etf":0,"ttmEps":2.014185,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":5,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":28.94,"dividendRate":0.046929,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.945047,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"1197256636","title":"异动解读｜巨子生物盘中下跌5.27%，报27.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256636","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197256636?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:40","pubTimestamp":1784256058,"startTime":"0","endTime":"0","summary":"7月17日，巨子生物盘中下跌5.27%，报27.96港元，成交额5563.98万港元。巨子生物所在的个人用品行业中，板块整体表现偏弱，个股中，毛戈平跌5.06%，上美股份跌4.23%，不同集团跌3.87%，乐舒适跌1.87%，恒安国际涨1.5%。巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113021524","title":"异动解读｜巨子生物盘中上涨5.13%，医美矩阵密集落地机构看好基本面拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=1113021524","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113021524?lang=zh_cn&edition=full","pubTime":"2026-07-16 11:21","pubTimestamp":1784172107,"startTime":"0","endTime":"0","summary":"7月16日，巨子生物盘中上涨5.13%，报29.9港元，成交额1.25亿港元。消息面上，公司医美产品矩阵近期密集落地，延续前一交易日涨势。6月以来，巨子生物旗下753胶原针正式上市，为国内首个重组Ⅰ型胶原蛋白面部注射剂；同月公司自研交联重组Ⅲ型全长序列胶原蛋白填充剂获NMPA批准，为全球首款用于改善颈纹的同类产品。华创证券研报指出，公司医美矩阵已逐步成型，化妆品舆论风险逐步出清拐点初现。中金、东方证券等多家机构维持正面评级，目标价区间40-43港元，看好公司基本面改善趋势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651581114","title":"港股异动 | 美妆板块涨幅居前 618美妆大盘双位数增长 机构预计美妆行业二季度延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651581114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651581114?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:49","pubTimestamp":1784101798,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348767384.USD","LU2242644610.SGD","LU2488822045.USD","02657","LU0502904849.HKD","LU0348766576.USD","02367","BK1207","SG9999004311.SGD","LU0455707207.USD","02145","01318"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171158691","title":"异动解读｜巨子生物盘中上涨5.28%，医美矩阵加速成型机构看好拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=1171158691","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171158691?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:53","pubTimestamp":1784084012,"startTime":"0","endTime":"0","summary":"7月15日，巨子生物盘中上涨5.28%，报28.32港元，成交额7072.03万港元。消息面上，巨子生物医美产品矩阵近期密集落地。华创证券研报指出，公司医美矩阵已逐步成型，化妆品舆论风险逐步出清拐点初现。中金、东方证券等多家机构维持正面评级，目标价区间40-43港元，看好公司基本面改善趋势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651289171","title":"【券商聚焦】中信证券：预计美妆行业在次季延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651289171","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651289171?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:55","pubTimestamp":1783990545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，22026Q2，预计美妆行业在需求疲弱、流量成本走高、内容运营压力加大的背景下延续低速增长；结构性进一步分化，国际高端品牌销售反弹，本土大众、中端定位品牌承压；毛戈平、林清轩延续高增长，巨子生物、贝泰妮、敷尔佳销售底部回升。2026Q2，医美板块上游产品供给增加，竞争延续较高强度，四环医药受益于自主产品上市继续提升市场份额。估值已充分反映当前的经营压力且已严重低估，静候基本面改善和估值回升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","BK1583","BK1516","LU1328615791.USD","LU1064131003.USD","02138","KCE","BK1215","BK1515","BK1600","LU0405327494.USD","LU1997245177.USD","SG9999004311.SGD","BK1585","02373","BK0276","LU1064130708.USD","02196","01696","LU1255011170.USD","LU1794554557.SGD","01530","BK1161","BK0012","BK0028","BK0196","BK1207","LU1655091616.SGD","LU1997244956.HKD","LU2289578879.USD","00460","BK1521","LU1720050803.USD","600030","06699","BK1100","BK0188","BK1147","BK1511","BK1564","BK0183","LU1580142542.USD","HK0000165453.HKD","LU1997245094.SGD","02367","LU2148510915.USD","06030","LU2495084118.USD","LU2488822045.USD","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907973","title":"港股异动 | 巨子生物(02367)盘中涨超6% 巨子生物医美矩阵扩张 机构指舆论风险逐步出清","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907973","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907973?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:56","pubTimestamp":1783666564,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巨子生物盘中涨超6%，截至发稿，涨4.13%，报26.22港元，成交额1.6亿港元。消息面上，巨子生物医美矩阵近期扩张。6月，巨子生物旗下753胶原针正式上市，为国内首个重组Ⅰ型胶原蛋白面部注射剂，差异化切入以Ⅲ型胶原为主流的注射市场。同月，公司自研交联重组Ⅲ型全长序列胶原蛋白填充剂获NMPA批准，为全球首款用于改善颈纹的同类产品。华创证券发布研报称，巨子生物医美矩阵已逐步成型，化妆品舆论风险逐步出清拐点初现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK4585","BK1207","SG9999004311.SGD","02367","KCAI","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115556291","title":"异动解读｜巨子生物盘中上涨5.08%，医美双证落地叠加618表现亮眼催化反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1115556291","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115556291?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:32","pubTimestamp":1783650729,"startTime":"0","endTime":"0","summary":"7月10日，巨子生物盘中上涨5.08%，报26.46港元，成交额5467.11万港元。消息面上，近期多家券商发布医美化妆品6月月报，重点提及巨子生物医美矩阵加速扩张。公司由此成为全球首家同时持有重组Ⅰ型和Ⅲ型胶原医美植入剂的企业。此外，618大促期间可复美抖音渠道GMV同比增长超40%，品牌基本盘企稳回升。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103859896","title":"巨子生物6月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1103859896","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103859896?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:57","pubTimestamp":1783069041,"startTime":"0","endTime":"0","summary":"巨子生物控股有限公司于2026年7月3日发布了截至2026年6月30日的证券变动月报表。公告显示，截至本月底，公司法定/注册股本总额维持在5,000,000,000股，面值为每股0.00001美元，法定/注册股本总金额仍为50,000美元，较上月底无变化。在已发行股份及库存股方面，截至6月30日，巨子生物的普通股已发行股份数目为1,061,704,000股，库存股份数目为0股，均与上个月保持一致。公司当月无新增发行、回购或注销股份的情况，亦无库藏股变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647325652","title":"618大促美妆类目取得10%+GMV增速 美妆板块强势 上美股份(02145)涨11.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647325652","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647325652?lang=zh_cn&edition=full","pubTime":"2026-06-29 14:13","pubTimestamp":1782713610,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美妆板块强势，上美股份 涨11.01%，毛戈平涨7.61%，巨子生物涨5.12%。消息面上，东方证券发布研报称，今年618各大平台摒弃冗长的定金机制，全面转向首发即现货的单品直接让利。中信证券表示，本次618大促电商大盘增速降至中单位数、美妆类目取得10%+GMV增速。同时品牌投流向主流平台和核心品类集中，或将加剧流量竞争和投流成本。维持美妆行业“强于大市”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01318","02145","LU0348767384.USD","LU0348766576.USD","BK1207","LU2242644610.SGD","LU0502904849.HKD","LU2488822045.USD","LU0455707207.USD","SG9999004311.SGD","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176282011","title":"异动解读｜巨子生物盘中上涨6.43%，618战报超预期叠加个人用品板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1176282011","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176282011?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:02","pubTimestamp":1782709335,"startTime":"0","endTime":"0","summary":"6月29日，巨子生物盘中上涨6.43%，报27.46港元，成交额8313.1万港元。个人用品板块集体走强，上美股份涨14.07%，毛戈平涨9.19%。消息面上，公司近日公布618大促战报，可复美线上全渠道GMV同比增长超25%，可丽金全周期GMV同比增长超30%，可复美成功扭转去年同期下滑趋势。多家券商维持买入或跑赢行业评级，看好公司基本面改善趋势及医美业务商业化进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647879344","title":"【券商聚焦】中信证券：美妆大盘增长降速 仍维持行业“强于大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647879344","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647879344?lang=zh_cn&edition=full","pubTime":"2026-06-29 09:14","pubTimestamp":1782695653,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，本次618大促电商大盘增速降至中单位数、美妆类目取得10%+GMV增速。当前主流平台均加强扶优战略，淘天品牌集中度提升，头部品牌稳健增长；抖音获国际品牌加码投入，国货份额下降、品牌表现分化。同时品牌投流向主流平台和核心品类集中，或将加剧流量竞争和投流成本。维持美妆行业“强于大市”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984659","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0502904849.HKD","SG9999004311.SGD","02145","02367","BK1207","LU2242644610.SGD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124468057","title":"异动解读｜巨子生物盘中下跌5.18%，消费板块估值承压叠加前日涨幅回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1124468057","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124468057?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:13","pubTimestamp":1782353639,"startTime":"0","endTime":"0","summary":"6月25日，巨子生物盘中下跌5.18%，报24.9港元，成交额3268.34万港元。个人用品行业整体走弱，板块内不同集团跌8.32%、毛戈平跌3.94%、上美股份跌2.62%。消息面上，此前中金发布研报指出港股消费板块整体估值中枢承压，下调巨子生物目标价18%至40港元。该股昨日因交联重组胶原蛋白植入剂获批消息刺激大涨5.45%，今日出现获利回吐压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195069610","title":"异动解读｜巨子生物盘中上涨5.45%，交联重组胶原蛋白植入剂获批提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1195069610","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195069610?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:47","pubTimestamp":1782269238,"startTime":"0","endTime":"0","summary":"6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。当前个人用品行业整体承压，巨子生物逆势走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645100350","title":"中金：维持巨子生物(02367)“跑赢行业”评级 目标价降至40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645100350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645100350?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:46","pubTimestamp":1782096394,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持巨子生物(02367)“跑赢行业”评级，基于港股消费板块整体估值中枢承压，下调目标价18%至40港元。该行维持巨子生物26至27年盈利预测。当前股价对应预测26及27年市盈率12及11倍。报告中称，巨子生物旗下“交联重组胶原蛋白填充剂”三类医疗器械获批，该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，差异化优势突出。同时公司首款获批医美产品已于6月9日正式发布上市，化妆品业务边际提速趋势显现，看好公司基本面改善趋势，建议关注底部布局机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644772267","title":"【券商聚焦】东方证券：巨子生物(02367)医美业务破局与护肤基本盘改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2644772267","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644772267?lang=zh_cn&edition=full","pubTime":"2026-06-18 14:41","pubTimestamp":1781764919,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东方证券发布研报指，巨子生物 近期核心投资看点来自医美业务破局与护肤基本盘改善，维持“买入”评级，目标价43.07港元。东方证券认为，该产品将助力公司构建械三、械二及护肤品的全品类矩阵，覆盖医疗美容、生活美容及家庭美容全场景。基于2025年报并考虑两大品牌表现及医美新品上市，东方证券调整盈利预测，预计2026-2028年归母净利润分别为20.94/22.99/25.53亿元。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984080","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0183","BK0028","BK1147","02367","BK1207","BK1564","SG9999004311.SGD","03958","BK0012","600958","LU2488822045.USD","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","BK1197","LU2476274308.USD","LU0348766576.USD","LU0348783233.USD","LU0417516902.SGD","SG9999004311.SGD","LU0417516571.SGD","01789","02268","BK1207","LU0561508036.HKD","BK1191","LU0640798160.USD","01099","IE00B5MMRT66.SGD","LU2399975544.HKD","LU0588546209.SGD","LU1720050803.USD","LU2476274720.SGD","01530","LU1969619763.USD","BK1161","06160","LU1303224171.USD","LU0348767384.USD","IE00B3M56506.USD","BK1515","LU0348784397.USD","BK1588","03933","02196","BK1574","LU1770034418.SGD","LU0348735423.USD","601066","LU2328871848.SGD","SG9999014674.SGD","BK1500","02228","02367","09926","BK1585","IE00BPRC5H50.USD","LU0348827113.USD","BK1141","BK1100","09688","06821","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644571407","title":"巨子生物：附属公司交联重组胶原蛋白植入剂获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2644571407","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644571407?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:02","pubTimestamp":1781686920,"startTime":"0","endTime":"0","summary":"6月17日，巨子生物（02367）发布公告，全资附属公司陕西巨子生物技术有限公司交联重组胶原蛋白植入剂获医疗器械注册证。本产品采用人III型成熟胶原蛋白全长序列，该序列共1068个氨基酸，完整保留胶原蛋白的天然功能域，并采用无化学交联剂残留风险的物理交联工艺，形成稳定的三维网状凝胶，用于颈部皮内真皮层注射填充，以纠正颈部中重度横纹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173774630013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","02367","159883","BK1583","SG9999004311.SGD","LU2488822045.USD","BK1207","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103121576","title":"巨子生物控股公司获中国医疗器械注册证：交联重组胶原蛋白植入剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1103121576","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103121576?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:34","pubTimestamp":1781685255,"startTime":"0","endTime":"0","summary":"巨子生物控股公司宣布，其交联重组胶原蛋白植入剂产品已正式获得中国医疗器械注册证。这一注册标志着该创新产品获准在中国市场进行商业销售与应用，是公司产品管线商业化进程中的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","02367","BK1207","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643758665","title":"【券商聚焦】国泰海通维持巨子生物(02367)增持评级 指高基数阶段已过&新品有望拉动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2643758665","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643758665?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:15","pubTimestamp":1781601327,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券发布研报指，巨子生物 高基数阶段已过，后续护肤及医美新品有望拉动增长，维持目标价40.68港元及“增持”评级。公司主品牌可复美2026年初承压，但618大促期间排名企稳，抖音渠道GMV同比增长超40%，品牌力及运营基础优秀。展望下半年，25年同期低基数叠加新品及运营优化，后续有望边际改善。新品方面，可复美4月上线焦点系列次抛大单品“超透棒”，首周全渠道自营GMV突破3000万，与修复定位的胶原棒形成差异化。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983920","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","02367"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02367","SG9999004311.SGD","01696","01530","LU2488822045.USD","BK1161","00460","BK1583","06826","BK1515","00719","BK1593","BK1600","HK0000165453.HKD","BK1585","BK1100","BK1207"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":0.0758},{"period":"1month","weight":0.134},{"period":"3month","weight":-0.0524},{"period":"6month","weight":-0.1266},{"period":"1year","weight":-0.5022},{"period":"ytd","weight":-0.0883}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家主要从事基于生物活性成分的美丽与健康产品的研发、制造及销售业务的投资控股公司。该公司的主要产品包括功效性护肤品、医用敷料等专业皮肤护理产品，以及保健食品及其他产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.063748},{"month":2,"riseRate":0.75,"avgChangeRate":0.082293},{"month":3,"riseRate":0.75,"avgChangeRate":0.04973},{"month":4,"riseRate":0.75,"avgChangeRate":0.023756},{"month":5,"riseRate":0.25,"avgChangeRate":-0.038833},{"month":6,"riseRate":0.25,"avgChangeRate":-0.059254},{"month":7,"riseRate":0.5,"avgChangeRate":-0.012078},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018735},{"month":9,"riseRate":0.666667,"avgChangeRate":0.061774},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.12614},{"month":11,"riseRate":0.333333,"avgChangeRate":0.019826},{"month":12,"riseRate":0.25,"avgChangeRate":0.047111}],"exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}